Skip to main content

Gassert Chad's Form 4 filing

Ani Pharmaceuticals IncANIP · filed Mar 22, 2022

Accession no.
0001415889-22-003267
Filed
Mar 22, 2022
Trade date
Mar 18-21, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $275.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gassert ChadCIK 0001871002Officer (SVP - CORP. DEV. & STRATEGY)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 18, 2022Common StockPPurchaseAcquired+5,000$27.15F1+$135,750388,226Indirect
Mar 21, 2022Common StockPPurchaseAcquired+5,000$27.87F3+$139,350393,226Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The shares were acquired in multiple trades at prices ranging from $27.06 to $27.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

F3

The shares were acquired in multiple trades at prices ranging from $27.69 to $28.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)